Skip to main content
Daily Report

Daily Respiratory Research Analysis

01/22/2025
3 papers selected
3 analyzed

Three high-impact studies advance respiratory medicine: (1) a translational Science Translational Medicine study identifies a congenital, conserved innate immune dysfunction in cystic fibrosis from birth; (2) a JAMA analysis shows a COPD polygenic risk score improves identification of undiagnosed COPD beyond symptom-based case finding; and (3) a PLoS Biology investigation reveals emergent SARS-CoV-2 subgenomic RNAs that boost viral fitness and interferon evasion.

Summary

Three high-impact studies advance respiratory medicine: (1) a translational Science Translational Medicine study identifies a congenital, conserved innate immune dysfunction in cystic fibrosis from birth; (2) a JAMA analysis shows a COPD polygenic risk score improves identification of undiagnosed COPD beyond symptom-based case finding; and (3) a PLoS Biology investigation reveals emergent SARS-CoV-2 subgenomic RNAs that boost viral fitness and interferon evasion.

Research Themes

  • Early-life innate immune dysregulation in cystic fibrosis
  • Genomic risk scores to enhance COPD case-finding
  • Viral RNA-level evolution enabling immune evasion

Selected Articles

1. Perinatal dysfunction of innate immunity in cystic fibrosis.

86.5Level IIICohort
Science translational medicine · 2025PMID: 39841805

Using newborn CF pigs and preschool children with CF, the authors show a conserved perinatal innate immune defect characterized by increased immature myeloid infiltration, reduced CD16, and impaired phagocytosis/ROS generation before infection begins. These findings suggest CF lung disease is preceded by congenital innate immune dysfunction that may persist despite CFTR modulation.

Impact: Reframes CF pathogenesis as a congenital innate immune defect beginning at birth, opening avenues for early immune-targeted interventions alongside CFTR modulation.

Clinical Implications: Supports early-life immune monitoring in CF, exploration of adjunct immunomodulation (e.g., enhancing phagocytosis/ROS or monocyte maturation), and refining infection-prevention strategies beginning in the perinatal period.

Key Findings

  • Newborn CF pigs exhibit increased monocyte infiltration and immature myeloid profiles in lungs before infection; neutrophil numbers unchanged.
  • Decreased CD16 expression in myeloid cells is shared in CF pigs at birth and preschool children, correlating with reduced phagocytosis and ROS.
  • Findings indicate a congenital, translationally conserved innate immune aberration in CF.

Methodological Strengths

  • Cross-species validation (newborn CF pigs and preschool children) with concordant cellular and transcriptomic phenotypes.
  • Multimodal profiling (flow cytometry and transcriptomics) linking surface markers to functional deficits (phagocytosis/ROS).

Limitations

  • Human sample sizes and detailed demographics are not specified; human data appear cross-sectional.
  • Causality and modifiability of innate defects under CFTR modulation were not directly tested.

Future Directions: Test whether early immunomodulation can normalize myeloid maturation/function in CF infants; delineate interactions with CFTR modulators; longitudinal birth cohorts to link innate defects to clinical outcomes.

In patients with cystic fibrosis (CF), repeated cycles of infection and inflammation eventually lead to fatal lung damage. Although diminished mucus clearance can be restored by highly effective CFTR modulator therapy, inflammation and infection often persist. To elucidate the role of the innate immune system in CF etiology, we investigated a CF pig model and compared these results with those for preschool children with CF. In newborn CF pigs, we observed changes in lung immune cell composition before the onset of infection that were dominated by increased monocyte infiltration, whereas neutrophil numbers remained constant. Flow cytometric and transcriptomic profiling revealed that the infiltrating myeloid cells displayed a more immature status. Cells with comparably immature transcriptomic profiles were enriched in the blood of CF pigs at birth as well as in preschool children with CF. This pattern coincided with decreased CD16 expression in the myeloid cells of both pigs and humans, which translated into lower phagocytic activity and reduced production of reactive oxygen species in both species. These results were indicative of a congenital, translationally conserved, and functionally relevant aberration of the immune system in CF. In newborn wild-type pigs,

2. Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasion.

84.5Level IIICohort
PLoS biology · 2025PMID: 39836705

The study identifies convergently evolved, novel TRSs in SARS-CoV-2 that generate subgenomic RNAs—including a truncated N sgRNA—enhancing viral replication via antagonism of type I interferon. These RNA-level innovations occur across multiple lineages (e.g., B.1.1, Alpha, Gamma, Omicron), revealing a functional evolutionary layer beyond amino acid substitutions.

Impact: Reveals a new RNA-level mechanism of immune evasion and fitness, informing surveillance for neo-TRSs and strategies for antivirals/vaccines resilient to sgRNA-mediated escape.

Clinical Implications: Encourages genomic surveillance to track emergent TRSs; suggests considering TRS/sgRNA targets for therapeutics; highlights that variant risk cannot be judged by spike mutations alone.

Key Findings

  • Convergent emergence of novel TRSs upstream of Spike and Envelope in multiple lineages.
  • A prevalent neo-TRS within Nucleocapsid (B.1.1 lineage and VOCs) generates a truncated N sgRNA that antagonizes type I interferon and enhances fitness.
  • Distinct phenotypes arise when abrogating the TRS versus mutating N coding sequence, implicating functional RNA-level evolution.

Methodological Strengths

  • Integrated global genomics with mechanistic validation (sgRNA expression, IFN antagonism, fitness assays).
  • Demonstrated convergent evolution across lineages, strengthening generalizability.

Limitations

  • In vivo relevance in humans inferred; direct clinical outcome correlations were not reported.
  • Quantitative epidemiologic impact of each neo-TRS on transmission was not modeled.

Future Directions: Incorporate TRS/sgRNA features into variant risk assessment; develop inhibitors targeting TRS-mediated transcription; longitudinally link neo-TRS emergence to clinical severity and transmissibility.

Coronaviruses express their structural and accessory genes via a set of subgenomic RNAs, whose synthesis is directed by transcription regulatory sequences (TRSs) in the 5' genomic leader and upstream of each body open reading frame. In SARS-CoV-2, the TRS has the consensus AAACGAAC; upon searching for emergence of this motif in the global SARS-CoV-2 sequences, we find that it evolves frequently, especially in the 3' end of the genome. We show well-supported examples upstream of the Spike gene-within the nsp16 coding region of ORF1b-which is expressed during human infection, and upstream of the canonical Envelope gene TRS, both of which have evolved convergently in multiple lineages. The most frequent neo-TRS is within the coding region of the Nucleocapsid gene, and is present in virtually all viruses from the B.1.1 lineage, including the variants of concern Alpha, Gamma, Omicron and descendants thereof. Here, we demonstrate that this TRS leads to the expression of a novel subgenomic mRNA encoding a truncated C-terminal portion of Nucleocapsid, which is an antagonist of type I interferon production and contributes to viral fitness during infection. We observe distinct phenotypes when the Nucleocapsid coding sequence is mutated compared to when the TRS alone is ablated. Our findings demonstrate that SARS-CoV-2 is undergoing evolutionary changes at the functional RNA level in addition to the amino acid level.

3. Polygenic Risk Score Added to Conventional Case Finding to Identify Undiagnosed Chronic Obstructive Pulmonary Disease.

73Level IICohort
JAMA · 2025PMID: 39841442

In over 7,400 adults without prior COPD diagnosis, adding a COPD polygenic risk score to a modified Lung Function Questionnaire improved AUCs for detecting spirometry-defined COPD and correctly reclassified 13.8% of cases in FHS (though not in COPDGene). Results support integrating PRS to prioritize spirometry in case finding.

Impact: Operationalizes precision medicine in primary care by improving COPD case-finding yield beyond symptoms and risk factors, potentially reducing underdiagnosis.

Clinical Implications: PRS could guide spirometry allocation in asymptomatic/high-risk adults; implementation should consider ancestry-specific performance and health equity.

Key Findings

  • Adding PRS to mLFQ improved AUC from 0.78 to 0.84 (FHS), 0.69 to 0.72 (COPDGene non-Hispanic African American), and 0.75 to 0.78 (COPDGene non-Hispanic White).
  • At a 10% referral threshold, PRS+mLFQ correctly reclassified 13.8% (95% CI, 6.6%-21.0%) of COPD cases in FHS, but not in COPDGene.
  • Among 7480 participants without COPD history, 4.7% (FHS) and 18.9% (COPDGene) had spirometry-defined moderate to severe COPD.

Methodological Strengths

  • Large multi-cohort analysis across general and COPD-enriched populations with ancestry stratification.
  • Objective spirometric outcome and robust discrimination metrics (AUC, reclassification).

Limitations

  • Cross-sectional design limits causal inference and downstream clinical impact on outcomes.
  • Reclassification gains were not replicated in COPDGene; performance may vary by ancestry and cohort context.

Future Directions: Prospective trials to test PRS-guided spirometry pathways on diagnosis rates and outcomes; optimize PRS across ancestries; assess cost-effectiveness and implementation in primary care.

IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is often undiagnosed. Although genetic risk plays a significant role in COPD susceptibility, its utility in guiding spirometry testing and identifying undiagnosed cases is unclear. OBJECTIVE: To determine whether a COPD polygenic risk score (PRS) enhances the identification of undiagnosed COPD beyond a case-finding questionnaire (eg, the Lung Function Questionnaire) using conventional risk factors and respiratory symptoms. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis of participants 35 years or older who reported no history of physician-diagnosed COPD was conducted using data from 2 observational studies: the community-based Framingham Heart Study (FHS) and the COPD-enriched Genetic Epidemiology of COPD (COPDGene) study. EXPOSURES: Modified Lung Function Questionnaire (mLFQ) scores and COPD PRS. MAIN OUTCOMES AND MEASURES: The primary outcome was spirometry-defined moderate to severe COPD (forced expiratory volume in the first second of expiration/forced vital capacity [FEV1/FVC] <0.7 and FEV1 [percent predicted] <80%). The performance of logistic models was assessed using the PRS, mLFQ score, and PRS plus mLFQ score for predicting spirometry-defined COPD. RESULTS: Among 3385 FHS participants (median age, 52.0 years; 45.9% male) and 4095 COPDGene participants (median age, 56.8 years; 55.5% male) who reported no history of COPD, 160 (4.7%) FHS and 775 (18.9%) COPDGene participants had spirometry-defined COPD. Adding the PRS to the mLFQ score significantly improved the area under the curve from 0.78 to 0.84 (P < .001) in FHS, 0.69 to 0.72 (P = .04) in COPDGene non-Hispanic African American, and 0.75 to 0.78 (P < .001) in COPDGene non-Hispanic White participants. At a risk threshold for spirometry referral of 10%, the addition of the PRS to the mLFQ score correctly reclassified 13.8% (95% CI, 6.6%-21.0%) of COPD cases in FHS, but not in COPDGene. CONCLUSIONS AND RELEVANCE: A COPD PRS enhances the identification of undiagnosed COPD beyond a conventional case-finding approach in the general population. Further research is needed to assess its impact on COPD diagnosis and outcomes.